Exactmer awarded Knowledge Transfer Partnership with Queen Mary University of London

Exactmer, together with Queen Mary University of London (QMUL), has been awarded its first Knowledge Transfer Partnership (KTP), from Innovate UK.

Through this KTP, Exactmer and QMUL will develop new synthesis methods for exact Polyethylene Glycol polymers (PEGs), using Exactmer’s proprietary Nanostar Sieving Technology platform. When added to therapeutics drugs, PEGs help to regulate the transport and retention of the medicine in the body. Their water solubility also lends them useful in drug delivery scaffolds and nanomedicine. However, current manufacturing limitations means that producing PEGs is difficult to do accurately; to do so is challenging, time-consuming and expensive.

To solve this, Exactmer is developing its breakthrough technology, Nanostar Sieving, which could revolutionise PEG manufacturing. Through this KTP project, QMUL and Exactmer will address manufacturing and analytical challenges and will accelerate the commercialisation of exact PEGs for applications in the PEGylated drug and Antibody Drug Conjugates markets.

The KTP programme is a collaboration between universities and businesses in the UK, to help overcome challenges of innovation and address specific obstacles to technology development. It is a partially-government funded initiative which gives companies access to the know-how and expertise of academic institutions, through a project designed to address a specific business need.

Exactmer and Queen Mary University of London are now hiring a Postdoctoral Research Chemist to work as KTP Associate on the project. You can apply for the role and see further details here.

For more information please contact the Exactmer team at sales@exactmer.com.


Exactmer wins Startup Pitch and Partner Award at BioVaria, Munich

Exactmer is delighted to have been awarded the Startup Pitch and Partner award in the ‘Emerging’ category, at BioVaria 2022.

Exactmer’s winning pitch on the development of our proprietary Nanostar Sieving technology for oligonucleotide synthesis was chosen by a jury of leading investors, in a showcase of 13 hand-picked start ups from across Europe.

BioVaria is Europe’s leading showcasing event for life-science technologies, targeting technology scouts, business developers and investors, and bringing together Europe’s leading tech transfer professionals, innovators from academia and representatives of the global biotech and pharma industry.

This year’s event was held in Munich in May, bringing together over 230 life-science innovators to the two-day event, with more than 60 licensable innovations presented by leading players from all over Europe, from therapeutic and diagnostic approaches to platform technologies.

Read the full feature here.